Columbia Pictures hopes audiences are craving new superhero action when Kraven the Hunter hits theaters on December 13th. This is the latest entry in the Sony Spider-Man Universe which has found success with the Venom pics and failure with Morbius and Madame Web. Aaron Taylor-Johnson stars in the title role spawned from the Marvel Comic with Ariana DeBose, Fred Hechinger, Alessandro Nivola, Christopher Abbott, and Russell Crowe offering support.
This has had a lengthy road to the multiplex. Hunter is on its fourth release date as it was originally slated for nearly two years ago. The first trailer came out in June 2023. In April of 2022, Morbius rolled out to a $39 million showing before cratering in weekend #2. Madame Web had a six-day rollout over President’s Day weekend and took in only $25 million for that time period.
I don’t think Kraven approaches that Morbius figure and it may fall just below Web‘s $15 million Friday to Sunday from a few months back.
Kraven the Hunter opening weekend prediction: $14.8 million
For my The Lord of the Rings: The War of the Rohirrim prediction, click here:
Disney seeks to break its own all-time biggest Thanksgiving weekend record when Moana 2 sails into multiplexes this Wednesday. It’s the sole wide release over the holiday and you can peruse my detailed prediction post on it here:
It could be close, but I’m projecting the sequel to 2016’s animated tale will exceed Frozen II‘s current largest three-day and five-day ($85.9 million and $125 million) takes over the Turkey Day frame. The follow-up should easily top the Thanksgiving Friday to Sunday mark for a new picture which is currently held by… Moana at $56 million.
Leftovers will populate the rest of the top 5 with Wicked posting a second place showing after its third best premiere of 2024 (more on that below). With an A Cinemascore grade, the decline may only be in the mid 30s or so.
Gladiator II will drop a notch to third after a start on the lower end of its anticipated range. Ridley Scott’s long-in-the-works sequel could lose close to half its debut audience.
Red One and Venom: The Last Dance should fill out the rest of the high five and here’s how I see it playing out:
1. Moana 2
Predicted Gross: $92.1 million (Friday to Sunday); $130.3 million (Wednesday to Sunday)
2. Wicked
Predicted Gross: $71.6 million
3. Gladiator II
Predicted Gross: $27.5 million
4. Red One
Predicted Gross: $9.4 million
5. Venom: The Last Dance
Predicted Gross: $2.9 million
Box Office Results (November 22-24)
Two things can be true as “Glicked” (Wicked and Gladiator II releasing on the same day) gave a needed jolt to the box office while each came in at the lower end of most projections. The critically acclaimed Wicked, based on the hugely popular play, made off with $112.5 million. As mentioned, it’s the third best haul in 2024 behind Deadpool & Wolverine and Inside Out 2. Yet it didn’t match my $134.6 million forecast. With magical word-of-mouth, this seems destined to perform well throughout the season.
Gladiator II was runner-up with $55 million and that didn’t measure up to my $69.8 million call. The so-so Cinemascore grade could mean its weekend to weekend declines could be heftier than I might’ve originally projected.
Red One slid to third at $13.2 million compared to my $14.9 million prediction. The holiday action comedy has taken in $52 million in two weeks which isn’t overly impressive considering the reported $250 million price tag.
Newcomer Bonhoeffer from Angel Studios was the only newcomer of the trio that opened above my expectations with $5 million. I said $4 million.
Venom: The Last Dance rounded out the top five with $3.8 million (I said $3.6 million) for $133 million in five weeks.
The Best Christmas Pageant Ever was sixth with $3.4 million, ahead of my $2.7 million projection for $25 million in three weeks. Behind it in seventh was Heretic with $2.2 million (I went with $2.5 million) for $24 million in three weeks.
Critically acclaimed horror thriller Heretic and holiday family dramedy The Best Christmas Pageant Ever will both attempt to keep Venom: The Last Dance from a third weekend in first place. You can peruse my detailed prediction posts on the newbies here:
Heretic finds Hugh Grant dipping into scary territory and my low double digits estimate puts it in range with the September start of Speak No Evil. That’s likely good for second place.
I’ve got Christmas in third in the high single digits though its chances of over performing exist. I also think it might experience low declines as the holidays approach and get off to a relatively slow start.
My projections on the two openers does indeed leave Venom atop the charts for a third frame assuming it drops in the mid 40s. Holdovers The Wild Robot and Smile 2 should round out the high five and here’s how I have it playing out:
1. Venom: The Last Dance
Predicted Gross: $14.3 million
2. Heretic
Predicted Gross: $11.2 million
3. The Best Christmas Pageant Ever
Predicted Gross: $8 million
4. The Wild Robot
Predicted Gross: $5.6 million
5. Smile 2
Predicted Gross: $4.4 million
Box Office Results (November 1-3)
November started off in multiplexes with October product holding steadier than my forecasts. Venom: The Last Dance is the prime example as it declined only 49% in weekend #2 with $25.9 million. I was much lower at $17.3 million. That’s a bit of a surprise considering predecessor Let There Be Carnage plummeted in the mid 60s. Of course, it’s worth noting that Dance opened with nearly $40 million less than Carnage.
The Wild Robot was second with $7.4 million as it managed to rise 9% and blast past my $5 million call. The animated pic has amassed $121 million after six weeks.
Smile 2 was third with $6.7 million and that’s wider than my $5.6 million take. The horror sequel is up to $52 million after three frames.
Oscar hopeful Conclave eased a mere 24% in fourth with $5 million (I said $4.2 million) for $14 million in two outings.
Finally, Robert Zemeckis’s Here, which reunites his Forrest Gump leads Tom Hanks and Robin Wright, stumbled with critics and audiences. The fifth place showing netted $4.8 million. My prediction? $4.8 million!
Robert Zemeckis reunites with his Forrest Gump leads Tom Hanks and Robin Wright some 30 years after that Best Picture recipient with the family drama Here this weekend. My detailed prediction post on the newcomer can be accessed here:
Here is likely to be the sole newbie to place in the top five. Unlike Gump, there’s no awards buzz for this. A debut in the mid single digits could mean anywhere from second to fifth.
Tom Hardy’s third and reportedly final go-round in The Last Dance had a subpar start (more on that below). With a troubling B- Cinemascore, a 60 percent plus percentage drop appears inevitable. That should mean mid or high teens for an unremarkable repeat performance in 1st place.
Holdovers Smile 2, The Wild Robot, and Conclave should fill out the rest of the high five and here’s how I have it playing out:
1. Venom: The Last Dance
Predicted Gross: $17.3 million
2. Smile 2
Predicted Gross: $5.6 million
3. The Wild Robot
Predicted Gross: $5 million
4. Here
Predicted Gross: $4.8 million
5. Conclave
Predicted Gross: $4.2 million
Box Office Results (October 25-27)
As mentioned, viewers were not grooving to Venom: The Last Dance. The comic book based sequel set in Sony’s Spider-Man Universe took in $51 million. That’s under my $62.3 million take and well below 2018’s Venom ($80 million) and 2021 follow-up Let There Be Carnage at $90 million. Crowds have clearly soured on the franchise.
The news wasn’t great for Smile 2 either. The horror sequel was second with $9.5 million and that represents a 59% plummet. Its 2022 predecessor only experienced an 18% decline in weekend #2. While I didn’t think that would occur, I had this pegged at $15.6 million during its follow-up frame.
The Wild Robot was third with $6.8 million compared to my $7.5 million call. The animated hit has taken in $111 million in five weeks.
Oscar hopeful Conclave with Ralph Fiennes was fourth with a better than anticipated $6.6 million. Edward Berger’s papal succession drama blew past my $4.8 million projection.
The Andrew Garfield/Florence Pugh romance We Live in Time added nearly 2000 screens and was fifth with $4.8 million. I incorrectly had it outside the top five as its total reached $11 million.
Finally, Terrifier 3 was sixth with $4.7 million (I said $5.4 million) for a robust $44 million in three weeks.
Tom Hardy and his title character alter ego are back for the third and allegedly final time when Venom: The Last Dance hits multiplexes this weekend. The only sub franchise in the Spider-Man Universe doing brisk business and producing sequels (sorry Morbius and Madame Web), Kelly Marcel directs. The supporting cast includes Chiwetel Ejiofor, Juno Temple, Rhys Ifans, Peggy Lu, Alanna Ubach, and Stephen Graham.
Critics haven’t been overly kind to Hardy and company. Part 1 from 2018 managed only 30% on Rotten Tomatoes and a 35 on Metacritic. 2021 follow-up Venom: Let There Be Carnage fared better with 57% on RT and a 49 Metacritic. Dance is currently falling between those numbers with a 41% Tomato meter and 42 on MC.
Even though Hardy gives it his bonkers all in this series, don’t put money down on a Best Actor nomination unless you plan to lose. As I wrote three years ago with Carnage, Visual Effects is really the only awards play. Neither of Dance‘s predecessors nabbed a nod in VE and I wouldn’t expect this one to contend. My Oscar Prediction posts will continue…
Tom Hardy is back in the threequel Venom: The Last Dance while awards hopeful Conclave also debuts Friday. You can peruse my detailed prediction posts on the weekend’s newcomers here:
Hardy’s latest go-round as the comic book symbiote will easily dominate the charts. Yet I’m not bullish that The Last Dance will top the openings of predecessors Venom from 2018 ($80 million) and 2021’s Venom: Let There Be Carnage ($90 million). I have it in the low to mid 60s.
Conclave is expected to nab a Best Picture nomination. Edward Berger’s follow-up to All Quiet on the Western Front may have to settle for a mid single digits start that should put it in fourth or fifth place.
As for holdovers, Smile 2 may benefit from its genre in weekend #2 as horror fans seek content. The first Smile rode a wave of loud buzz to a startling 18% decline in its second frame. I’d be surprised if the sequel sees that, but mid to high 30s seems feasible. The Wild Robot and Terrifier 3 should fill out the remainder of the high five.
Here’s how I see it playing out:
1. Venom: The Last Dance
Predicted Gross: $62.3 million
2. Smile 2
Predicted Gross: $15.6 million
3. The Wild Robot
Predicted Gross: $7.5 million
4. Terrifier 3
Predicted Gross: $5.4 million
5. Conclave
Predicted Gross: $4.8 million
Box Office Results (October 18-20)
Smile 2 was barely able to open wider than part 1 at $23 million. The original hit $22.6 million two years later. I had this making slightly more at $27 million. That’s a fair result though (as mentioned above) I wouldn’t expect this to have quite the sturdy legs of what came before.
The Wild Robot held in second with $10 million, on par with my $10.7 million forecast. The animated adventure is now north of nine digits after four weeks with $101 million.
Terrifier 3 slid from first to third with $9.3 million, in line with my $9.8 million call. The $38 million total in ten days is quite a feat considering the reported teensy $2 million price tag.
Beetlejuice Beetlejuice was fourth with $5 million (I went with $5.8 million) for a seven-week haul of $283 million and $300 million potentially in its domestic sights.
Finally, the Andrew Garfield/Florence Pugh rom dram We Live in Time expanded to just under 1000 venues and posted $4.1 million. I was close with $4.3 million. That brought the overall tally to $4.5 million.
Blogger’s Note (11/09): I am revising my estimate down from $205.2M to $195.2M. As opposed to the narrative below, that would now give it the #9 opening of all time behind its 2018 predecessor.
On November 11th, Black Panther: Wakanda Forever looks to score the second largest opening of the young decade and add another MCU pic to the top 10 debuts of all time. The sequel to 2018’s phenomenon has Ryan Coogler returning to the director’s chair. Early reactions are very positive saying that part 2 pays touching tribute to Chadwick Boseman, who played the title character in the original and passed away in 2020. Letitia Wright, Lupita Nyong’o, Danai Gurira, Winston Duke, Dominique Thorne, Tenoch Huerta, Martin Freeman, and Angela Bassett are among the large cast.
Wakanda is not expected to approach the $260 million that Spider-Man: No Way Home made out of the gate last December. It should, however, get beyond the $191 million that Doctor Strange in the Multiverse of Madness earned in May. If it does, it would land the #2 opening of the decade and the pandemic era.
In February of 2018, Black Panther rode a wave of sizzling buzz to a $202 million start over the Friday to Sunday portion of President’s Day weekend. For the four-day frame, it topped out at $242 million before eventually grossing $700 million domestically. The three-day premiere still stands at #8 all-time while the overall haul is 6th.
I do believe that all the Wakanda stars are lining up for a Friday to Sunday take that surpasses the original by a small margin. My estimate would give the new Panther the #8 opening while moving its predecessor down to ninth. Time will tell if it eventually approaches the $700 million that the first part amassed.
Black Panther: Wakanda Forever opening weekend prediction: $195.2 million
There are some Matrix adjacent fight scenes in Morbius that might have you thinking it should be called Morpheus. They’re nowhere near that level in quality and some of them are such a CG mess that you can’t tell what’s happening. Should our hero and villain bite the red artery or suck the blue vein? Despite its connective tissue to Sony’s Spider-Man Universe (meaning the web slinger and Venom), it’s hard to really care.
Dr. Michael Morbius (Jared Leto) is a world renowned expert in blood disorders. The experience is personal as he has one and makes it his life work to cure himself and others. His childhood friend Milo (Matt Smith) suffers from the same disease and has the money to bankroll Doc Mo’s research. A Costa Rican excursion results in the acquisition of vampire bats. Perhaps some genetic splicing will do the trick!
This is when Morbius is blessed and cursed with the batty sense. He feels better than ever (and looks jacked), but has to feast to keep the strength up. His desire to go full Dracula prevents him from offering the cure to Milo. That puts a strain on their friendship causing Milo to go full overacting bad guy.
While our title character tries to get by on artificial blood, many of the visual effects look pretty fake. There’s no real development of the supporting characters. This includes Adria Arjona as Morbius’s colleague/love interest, Jared Harris as his father figure and medical mentor, and Tyrese Gibson and Al Madrigal as detectives tracking the suckers. Maybe their time was cut. Maybe the filmmakers (with Daniel Espinosa in the director’s seat) are saving some for hoped for sequels. Tyrese is apparently signed for a three-picture deal which explains his curiously fast appearance.
In the first half, Morbius is a passable enough monster mash. Maybe even a little quaint as it sort of feels like a late 90s genre piece before most comic book movies came with $200 million budgets. I’m not sure I buy Leto as a brilliant physician turning down Nobel prizes, but he doesn’t embarrass himself. This sputters as the effects render it increasingly incomprehensible.
By the time it drops in Spidey references in the mid credits sequences, it’s gotten desperate. In this Spider-Verse, Morbius doesn’t reach the specific heights of the venomous creatures preceding it.
Sony and Marvel are hoping there’s plenty of buyers in the Morbius club as the dark superhero tale finally premieres on April 1st. Led by Jared Leto in the title vampiric role, Daniel Espinosa directs with a supporting cast including Matt Smith, Adria Arjona, Al Madrigal, and Tyrese Gibson.
This is the third entry in Sony’s Spider-Man Universe after the two Venom flicks from 2018 and last year. Both of them were massive hits and, of course, we are on the heels of Spider-Man: No Way Home being the third largest domestic earner in history.
Morbius was originally set for release all the way back in summer of 2020 before its numerous COVID related delays. Shot for a reported $75 million, it should have no trouble making its money back (especially when including international grosses). Yet I’m skeptical it approaches the $80 million that Venom started with or $90 million that its sequel earned out of the gate a few months back.
Estimates are in the $40-$50 million range and my hunch is that projecting a debut in the middle end of that range is the call.
There’s a sequence in Venom: Let There Be Carnage where Woody Harrelson’s serial killer villain engages in mayhem with his crazy girlfriend (Naomie Harris). The deadly duo wreak their havoc in a ’66 Mustang and, for a moment, I was reminded of the actor’s appearance nearly 30 years ago in Natural Born Killers. Call it Muckey and Mallory this time as the amount of extraterrestrial goo is easily doubled in this sequel.
Speaking of natural born killers, it’s an apt description for the title character. The alien symbiote longs to bite humans heads off, but he’s mostly under control due to his human host Eddie Brock (Tom Hardy). Poor Venom has to settle for chickens. Continuing the banter that was the highlight of the original, Carnage still allows for Hardy’s bizarre but oddly effective comedic performance.
For those who forgot (and 2018’s Venom was a bit forgettable), Eddie is a San Francisco based journalist whose expose into scientific experiments stuck him with the black liquid alien that now lives in his body. Our loony reporter is put on assignment when Detective Mulligan (Stephen Graham) tasks Eddie with extracting evidence from death row condemned psycho Cletus Kasady (Woody Harrelson).
Their jailhouse interview leads to chaos and Carnage – as in the name of a Venomous offspring that invades the already crazed Cletus. And there’s the aforementioned love interest played by Harris. Confined to the Ravencroft Institute (where we first met Cletus in a Venom post-credits bit), Frances Barrison can manipulate sound to get herself out of sticky situations. This earns her the moniker Shriek due to those deadly decibels.
Andy Serkis is in the director’s chair (replacing Ruben Fleischer) and he keeps Carnage short, light, and full of CG action. The screenplay strains a little to justify bringing back Michelle Williams as Eddie’s ex-flame. I suppose someone’s gotta get saved by the hero in the third act. Reid Scott reprises his role as her boyfriend and there are a couple of humorous moments with his character.
I couldn’t quite recommend Venom though I came close solely based on Hardy’s batty work. This is no comic book masterwork and even the great Harrelson’s villainous turn is passable at best. Yet I more or less came around with Carnage. I give it props for foregoing a bloated running time (it’s just an hour and a half). It’s hard to not be entertained by Hardy and his skull chomping companion. In the constantly growing universe of comic book based franchises, it’s getting common for the sequels to improve upon the originals. The first entries always have to go through the origin story while the follow-ups can be a little more fun. That applies here.
All My Life... I Wanted To Be A Blogster 